| 2016-YEO-67581 | |
| Nearly 40 percent of active pharmaceutical ingredients under development are poorly soluble in aqueous media leading to low bioavailability and erratic absorption. In an attempt to solve this issue, researchers began to develop nanocrystals of these insoluble drugs. Nanocrystals have increased dissolution rates, offering increased solubility. However, fast-dissolving small nanocrystals provide little advantage to solution formulations, and larger nanocrystals are recognized by the immune system. In addition, current nanoparticle formulations can contain greater than 50 percent excipients; the excipients often present their own adverse effects, which limit the dose. Researchers at Purdue University have developed a method to produce pharmaceutical nanocrystals comprised of more than 85 percent of their respective active ingredients. These nanocrystals are coated with albumin to prevent the immune response and allow the nanocrystals to target cancerous cells unhindered. These nanocrystals have the potential to increase the effectiveness of a wide range of drugs as they contain a much greater percentage of active ingredients, allow for increased bioavailability, and avoid immune recognition. Advantages: -Increases bioavailability of insoluble drugs -Fewer adverse effects -Avoids immune recognition Potential Applications: -Drug formulation Related Publications: J. Park, et al., Albumin-coated nanocrystals for carrier-free delivery of paclitaxel. Journal of Controlled Release (2016). http://dx.doi.org/10.1016/j.jconrel.2016.12.040 |
|
|
|
|
Jun 15, 2017
Utility Patent
United States
10,398,651
Sep 3, 2019
Jun 16, 2016
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |